Complete enrollment for the EVOGUARD Phase 3 clinical trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- March 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Study remains on track to complete enrollment by YE 2021”
What we found
Evidence strength A What the grades mean
The company announced a goal to complete enrollment for the EVOGUARD trial by year-end 2021, but later filings confirm that enrollment was not completed until March 2022.
-
A Evofem Biosciences, Inc. 10-Q filed 2022-05-10
“We completed enrollment in March 2022” ✓ confirmed on the page
-
A Evofem Biosciences, Inc. 10-Q filed 2023-01-06
“the completion of enrollment in our Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women was delayed due in part due to challenges related to COVID-19” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- EVOGUARD Phase 3 trial enrollment
- Where
- US
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Evofem Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-EVFM-023208 · Corrections policy